ArticleEcancermedicalscience2026
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic NSCLC.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Resistance to epithelial growth factor receptor gene (EGFR)-tyrosine kinase inhibitors, both intrinsic and acquired, presents a major challenge in EGFR mutant non-small cell lung carcinoma (NSCLC), with the T790M mutation being the most common acquired resistance mechanism. Data on resistance patterns in the Indian population remains limited. Materials and methods: This Results: Of the 275 (78.6%) patients experiencing progressive disease (PD), a total of 206 patients were available for the final analysis after excluding patients without histological/molecular analysis.Histological transformation to small cell lung carcinoma (SCLC) occurred in 12 patients (6%), with various EGFR mutation statuses identified. T790M mutations were observed in 44 (37%) of 119 patients in the gefitinib arm and 17 (19%) of 87 patients in the gefitinib plus chemotherapy arm ( Interpretation: Emergence of T790M was lower than reported in previous studies, likely due to the addition of chemotherapy to gefitinib. T790M mutations were more prevalent in the gefitinib-alone arm. Histological transformation and loss of sensitising mutations highlight the importance of repeat biopsy and molecular testing to guide subsequent treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.